The Latest Breaking News from Vertex Pharmaceuticals

Over the past 3 months, 4 analysts have published their opinion on Vertex Pharmaceuticals (NASDAQ:VRTX) stock. These analysts are typically employed by large Wall Street banks and tasked with understanding a company's business to predict how a stock will trade over the upcoming year.

Vertex Pharmaceuticals's (NASDAQ:VRTX) short percent of float has risen 18.8% since its last report. The company recently reported that it has 4.01 million shares sold short, which is 1.58% of all regular shares that are available for trading.

Vertex Pharmaceuticals (NASDAQ:VRTX) has outperformed the market over the past 15 years by 7.35% on an annualized basis producing an average annual return of 15.26%. Currently, Vertex Pharmaceuticals has a market capitalization of $67.63 billion.

Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) released positive results from two Phase 2 post-operative trials for its non-opioid program, VX-548.  One trial looked at patients who had just received a bunionectomy (Correcting the deformity of toes & foot), the other in patients who received abdominoplasty (tummy tuck). Vertex said that within 48 hours of surgery,…

Vertex Pharmaceuticals (NASDAQ:VRTX) has outperformed the market over the past 5 years by 9.35% on an annualized basis.

Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX) creates new possibilities via medicine to cure diseases and improve people's lives, and over the past year, marked gains in investors’ portfolios.

Vertex Pharmaceuticals (NASDAQ:VRTX) reported its Q4 earnings results on Wednesday, January 26, 2022 at 04:01 PM. Here's what investors need to know about the announcement.

Over the past 3 months, 6 analysts have published their opinion on Vertex Pharmaceuticals (NASDAQ:VRTX) stock. These analysts are typically employed by large Wall Street banks and tasked with understanding a company's business to predict how a stock will trade over the upcoming year.